3Q sales, trends for key Bristol-Myers medicines

The Associated Press
Associated Press

Global sales of key Bristol-Myers Squibb drugs in 2012's third quarter:

Drug name Use 2012 Change from 2011

Plavix Blood thinner $64 million Down 96 percent

Avapro/Avalide High blood pressure $95 million Down 56 percent

Reyataz HIV/AIDS $363 million Down 7 percent

Abilify Psychiatric disorders $676 million Down 2 percent

Erbitux Various cancers $173 million Up 1 percent

Sustiva HIV/AIDS $370 million Up 3 percent

Baraclude Hepatitis B $346 million Up 11 percent

Sprycel Leukemia $263 million Up 25 percent

Orencia Rheumatoid arthritis $307 million Up 32 percent

Onglyza Type 2 diabetes $178 million Up 40 percent

Yervoy Melanoma $179 million Up 48 percent

___

Source: Bristol-Myers Squibb Co.